Exocrine Pancreatic Insufficiency (EPI) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Exocrine Pancreatic Insufficiency (EPI) Market Trends and Insights

Rising Prevalence of EPI Linked to Chronic Pancreatitis & Pancreatic Cancer

Chronic pancreatitis and pancreatic cancer together shape the largest at-risk cohort for enzyme replacement therapy. Longitudinal data show that 80-90% of chronic pancreatitis cases progress to exocrine pancreatic insufficiency, and up to 80% of pancreatic cancer patients ultimately manifest digestive insufficiency symptoms.^{[1]Luca Lambertini et al., “Pancreatic Cancer Epidemiology,” MDPI, mdpi.com} Despite the high incidence, real-world studies indicate that only 21% of symptomatic cancer patients receive guideline-recommended PERT, highlighting a sizable treatment gap. The disconnect is gradually closing as oncology guidelines emphasize early enzyme therapy alongside chemotherapeutic regimens. Heightened public health campaigns and improved imaging modalities are unveiling latent cases, transforming what was once acute palliation into a chronic supportive-care model that extends throughout a patient’s survival journey. Consequently, demand patterns are shifting toward high-volume, long-duration prescriptions that favor sustained revenue visibility for manufacturers.

Increasing Cystic-Fibrosis Survival Rates Expanding Lifetime Patient Pool

Decades ago, cystic fibrosis was primarily a pediatric fatality; today, median survival in developed markets exceeds 45 years, courtesy of CFTR modulator therapies.^{[2]Hannah Shields et al., “Adult Cystic Fibrosis Health Outcomes,” BMJ Open, bmj.com} Up to 85% of cystic-fibrosis patients exhibit pancreatic insufficiency at infancy and therefore initiate PERT soon after diagnosis. As these patients transition into adulthood and elderly age bands, lifetime prescription volumes multiply, embedding predictable, annuity-like demand for enzyme suppliers. Adult-centered care further magnifies product differentiation around pill burden, flavor masking, and digital dosing calculators that simplify adherence across diverse meal patterns. The sustained nature of therapy also strengthens the value proposition for long-acting recombinant options that reduce daily capsule counts, thereby improving quality of life and indirectly supporting nutritional status.

Patent Expiries Spurring Affordable Generics

Key intellectual-property protections surrounding leading porcine pancreatin brands begin to unwind in February 2028, notably for Zenpep. Once exclusivities lapse, abbreviated new-drug application pathways and the shift from NDA to BLA filing criteria unlock competitive entry, placing downward pressure on prices, especially in the United States where private insurers aggressively favor generics. Lower unit costs are expected to improve therapy accessibility in both mature and emerging regions, broadening the addressable patient pool. Brand incumbents are countering price erosion by investing in differentiated delivery formats, pediatric-friendly micro-granules, and value-added adherence apps, while simultaneously extending their geographic footprints into under-penetrated Asia-Pacific markets.

Supply-Chain Innovation in Microbial/Recombinant Enzymes

Recurring shortages of porcine pancreatin have elevated supply security from an operational consideration to a strategic imperative. Biotech innovators such as Entero Therapeutics are progressing adrulipase, a recombinant lipase produced in expression systems that bypass livestock sourcing constraints.^{[3]Entero Therapeutics, “Adrulipase Phase IIb Results,” enterotherapeutics.com} Recombinant platforms promise tighter batch-to-batch consistency, improved viral-safety profiles, and scalability that can flex with demand surges a critical attribute given periodic livestock-related disruptions. Equally relevant are dietary or religious restrictions that limit porcine product acceptance in specific countries; recombinant enzymes nullify those barriers, expanding global addressable volumes. As validation data mature, payers may reward synthetic formats for their lower supply-risk premiums and potentially enhanced bioavailability.

Intermittent Shortages of Porcine Pancreatin Supply

In 2024-2025, 96% of U.K. community pharmacies reported difficulty sourcing Creon, a shortage expected to linger through 2026. Root causes include a limited number of qualified slaughterhouses, batch-release testing delays, and pandemic-driven transportation bottlenecks. As inventory gaps widened, national regulators invoked Serious Shortage Protocols permitting pharmacists to make dose-for-dose substitutions, yet many patients rationed capsules or altered diets, risking malnutrition. The scarcity underscores the fragility of a supply chain reliant on a single animal source and catalyzes stakeholder interest in recombinant or microbial substitutes that circumvent porcine raw-material constraints.

Low Clinician Confidence; Sub-Therapeutic PERT Dosing

A cross-sectional survey showed that 40% of prescriptions contain enzyme units below guideline-recommended 40,000–50,000 lipase units per meal, while 72% of patients perceive their dosing as inadequate. Sub-optimal dosing often stems from limited gastroenterology access, variability in meal fat content, and physician concerns about pill burden. The under-dosing phenomenon exacerbates malabsorption-related complications, inflates healthcare costs through preventable hospitalizations, and suppresses potential market volume. Digital dose calculators integrated into mobile health applications are emerging as pragmatic countermeasures, yet broad implementation requires clinician buy-in and payer support.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Therapy: PERT Dominance Faces Synthetic Disruption

The exocrine pancreatic insufficiency market size for pancreatic enzyme replacement therapy held an 80.92% revenue share in 2025. Reliance on porcine-derived pancrelipase remains the norm because the formulation delivers the triad of lipase, amylase, and protease in ratios clinicians trust. Yet recombinant and microbial formulations, though representing under 5% of volume today, are clocking an 8.55% CAGR as they respond to supply insecurities and dietary constraints. The exocrine pancreatic insufficiency market share of synthetic enzymes is forecast to inch past 10.25% by 2031 as late-stage candidates like adrulipase accumulate phase III data.

Manufacturers of conventional PERT are deploying controlled-release micro-granules that withstand gastric acidity, while innovators explore immobilized enzyme cartridges compatible with enteral feeding pumps. Differentiation extends to ancillary services, mobile adherence platforms, tele-nutrition counseling, and patient-assistance programs—that lock in prescriber loyalty even as generic erosion looms. These converging developments suggest a future landscape where porcine and recombinant options coexist, each targeting specific patient segments based on allergy status, cultural preferences, and source-of-origin ethics.

By Disease Etiology: Chronic Pancreatitis Leadership Challenged by Cancer Growth

Chronic pancreatitis generated 34.55% of 2025 revenue thanks to high symptom prevalence and lifelong therapy duration. The segment benefits from well-established clinical referral pathways between gastroenterology and nutrition specialties, ensuring steady prescription renewals. Cystic-fibrosis patients, though numerically smaller, present a long-tail demand curve because enzyme dependency begins in early childhood and persists across decades. Post-surgical and idiopathic etiologies complete the residual market, often characterized by intermittent rather than perpetual dosing.

Pancreatic-cancer-related EPI, once a supportive adjunct to palliative care, now stands on the cusp of a volume inflection. An 7.79% CAGR to 2031 is anchored in double-digit survival gains linked to novel chemotherapy regimens such as Ipsen’s Onivyde approved in February 2024. The therapy extends life expectancy and thus enlarges the cumulative need for enzyme supplementation. Notably, oncology guidelines published in 2025 began advocating proactive enzyme replacement at the time of cancer diagnosis, a practice shift that could materially lift penetration rates in the next 5 years.

By Distribution Channel: Digital Transformation Accelerates Online Growth

Hospital pharmacies preserved a 50.76% sales share in 2025 due to their integral role at treatment initiation and their proximity to specialist consults. Institutional purchasing power grants these pharmacies favorable pricing tiers, which in turn influences formulary placement within integrated delivery networks. Retail chains continue to act as the bridge for chronic refills, especially in suburban geographies where hospital dispensaries are sparse.

However, online pharmacies are emerging as the system’s fastest-growing node, registering a 10.41% CAGR through 2031. The pandemic normalized doorstep delivery for chronic therapies, and regulatory allowances for e-prescriptions further removed friction. Digital platforms embed refill reminders, nutrition tracking, and clinician chat functions, minimizing missed doses. Yet product complexity remains a gating factor; portals must deploy pharmacists trained in titration nuances to uphold safety standards. The channel’s rise will likely spur collaborations between manufacturers and telehealth providers, integrating enzyme supply with remote dietitian consults.

Geography Analysis

North America retained a 41.22% revenue share in 2025, reflecting universal insurance coverage for approved PERT brands and a mature prescriber base familiar with high-dose regimens. Creon alone enjoys 93% preferred formulary placement across commercial and Medicare Part D plans. Nevertheless, episodic backorders linked to limited porcine gland supply have triggered payer scrutiny, nudging providers to consider future recombinant alternatives. Competitive dynamics may intensify as FDA guidances framed under the BLA pathway clarify requirements for biosimilar enzymes, accelerating generic filings post-2028.

Europe exhibits high clinical sophistication but is grappling with acutely constrained inventories. The European Medicines Agency expedited approval of Micrazym in June 2024 to diversify product availability. Despite this, 2025 surveys revealed U.K. patients resorting to dose rationing amid prolonged shortages. In response, national health systems are drafting contingency contracts that oblige suppliers to hold multi-month safety stocks, bolstering resilience until recombinant pipelines mature. Parallel developments in digital adherence tools exemplified by the MyCyFAPP app that customizes dosing based on meal photographs are quickly gaining traction among European cystic-fibrosis clinics.

Asia-Pacific is the fastest-growing region, charting a 6.29% CAGR through 2031 on the back of improved diagnostic reach, population aging, and rising chronic-disease burdens. Chinese epidemiological data reveal a disproportionate uptick in pancreatic cancer incidence among adults aged 35–49, a trend that directly feeds enzyme demand. Regulatory overhaul is equally salient: India’s 2024 revision of its National Essential Medicines List now explicitly names pancrelipase, streamlining public-hospital procurement. However, fragmented reimbursement and a reliance on imported brands keep treatment access uneven. Multinational firms are therefore partnering with regional contract manufacturers to establish local fill-and-finish capacity, simultaneously lowering tariffs and strengthening political goodwill.

Market Opportunities and Future Outlook

White-space in EPI care is centered on earlier diagnosis, optimized dosing, and supply-secure non-porcine options as intermittent pancreatin shortages continue to disrupt access in parts of Europe and the United Kingdom through 2026. Clinical development activity in 2026 supports this shift away from reliance on porcine pancrelipase alone. Anagram Therapeutics initiated a Phase 2 study of ANG003 in EPI (including cystic fibrosis) with an active comparator design versus Creon, while Aimmune Nestle Health Science US R&D initiated a Phase 2 study in adult EPI evaluating the investigational lipase NHS7108. These studies point toward near-term demand for differentiated enzyme profiles, including lipase-centric approaches, and for improved formulations that reduce pill burden and support more consistent fat absorption, particularly for long-duration users such as cystic-fibrosis patients.

A second opportunity area is diagnostic enablement and personalization, where sponsors are exploring alternatives to fecal elastase-only workflows. In April 2026, the University of Pittsburgh initiated a study using a functional Malabsorption Blood Test (MBT) to identify EPI in chronic pancreatitis and evaluate quality-of-life changes with PERT, reflecting interest in earlier, more objective detection and titration pathways. Alongside the market's shift toward online pharmacies and manufacturer-led digital dosing tools, there is room for integrated test-to-treat pathways, covering screening, dose calculation, refill adherence, and nutrition support, as well as device-assisted delivery options for tube-fed patients. Immobilized enzyme cartridges such as RELiZORB fit as a differentiated alternative to standard capsules for severe malabsorption.